According to a recent report from Jefferies, Incyte INCY has received positive feedback from physicians on ruxolitinib at EHA. After speaking to six physicians regarding their feedback on ruxolitinib, Jefferies remains confident in ruxolitinib's approval and a successful product launch.
In the report, Jefferies said, "Of the six physicians we asked about ruxolitinib use in PV, five physicians were positive on the data
in this indication. The one negative Dutch physician expressed the view that she thought it would provide limited incremental benefit for the majority of PV patients."
Incyte closed Friday at $17.57.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in